Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

seizures/emorragia

Il collegamento viene salvato negli appunti
Pagina 1 a partire dal 17 risultati

1,2,4-triazolo[4,3-b]pyridazine derivatives and their use

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This invention relates to certain 1,2,4-triazolo[4,3-b]pyridazines, to pharmaceutical compositions containing them, to processes for their preparation and to their use in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is

Systems, devices and methods for the treatment of neurological disorders and conditions

Solo gli utenti registrati possono tradurre articoli
Entra registrati
TECHNICAL FIELD The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,

Systems, devices and methods for the treatment of neurological disorders and conditions

Solo gli utenti registrati possono tradurre articoli
Entra registrati
TECHNICAL FIELD The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,

Systems, devices and methods for the treatment of neurological disorders and conditions

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This application is also related to the following copending applications: U.S. application Ser. No. 12/898,685, entitled "Extracranial Implantable Devices, Systems and Methods for Treatment of Neuropsychiatric Disorders," filed on even date herewith with U.S. application Ser. No. 12/898,686,

Aryl sulfonamides and sulfamide derivatives and uses thereof

Solo gli utenti registrati possono tradurre articoli
Entra registrati
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic

Aryl sulfonamides and sulfamide derivatives and uses thereof

Solo gli utenti registrati possono tradurre articoli
Entra registrati
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic

Aryl sulfonamides and sulfamide derivatives and uses thereof

Solo gli utenti registrati possono tradurre articoli
Entra registrati
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic

Substituted quinoxaline-2-ones as glutamate receptor antagonists

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both

Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The

Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a or b position by amino acid derivatives. The compounds are active as excitatory amino
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to a method for identifying agents effective in modulating prokineticin receptor, and more specifically to the treatment of cerebrovascular diseases and seizure disorders. 2. Background

Therapeutic agents

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This is a 371 application of PCT/EP 94/03364 filed on Oct. 12, 1994. This invention relates to derivatives of 1,2,4-triazolo[1,5-a]pyrimidines, to pharmaceutical compositions containing them, to processes for their preparation and to their use in the treatment and/or prophylaxis of seizures,

Therapeutic use of compounds

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This invention relates to uses of compounds. In particular, it relates to the use of compounds in the treatment or prevention of diseases and biomedical conditions such as, seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent

Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION The present invention concerns novel urea and thiourea derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by urea or thiourea derivatives. The

Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents

Solo gli utenti registrati possono tradurre articoli
Entra registrati
The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds which have affinity for 5-HT.sub.1A receptors and which inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their
Unisciti alla nostra
pagina facebook

Il database di erbe medicinali più completo supportato dalla scienza

  • Funziona in 55 lingue
  • Cure a base di erbe sostenute dalla scienza
  • Riconoscimento delle erbe per immagine
  • Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
  • Leggi le pubblicazioni scientifiche relative alla tua ricerca
  • Cerca le erbe medicinali in base ai loro effetti
  • Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti

Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate

Google Play badgeApp Store badge